Multivariable risk of developing new onset diabetes after transplant-results from a single-center study of 481 adult, primary kidney transplant recipients

Clinical Transplantation

Volumn 29, Issue 4, 2015, Pages 301-310

  Ciancio, Gaetano ^a   Guerra, Giselle ^a   Sageshima, Junichiro ^a   Hanson, Lois ^a   Roth, David ^a   Goldstein, Michael J ^a   Chen, Linda ^a   Kupin, Warren ^a   Mattiazzi, Adela ^a   Tueros, Lissett ^a   Flores, Sandra ^a   Barba, Luis J ^a   Lopez, Adrian ^a   Rivas, Jose ^a   Ruiz, Phillip ^a   Vianna, Rodrigo ^a   Burke, George W ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Kidney transplantation; Multivariable risk factors; New onset diabetes after transplant

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; DACLIZUMAB; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; DEMOGRAPHY; DIABETES MELLITUS; DRUG MEGADOSE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT OUTCOME; ADVERSE EFFECTS; AGE; CLINICAL TRIAL; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; POSTOPERATIVE COMPLICATION; PROGNOSIS; RISK FACTOR;

ADULT; AGE FACTORS; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANT RECIPIENTS;

EID: 84927912385     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12510     Document Type: Article

References (55)

1. Boudreaux JP, McHugh L, Canafax DM et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 1987: 44: 376.
2. Sumrani NB, Delaney V, Ding Z et al. Diabetes mellitus after renal transplantation in the cyclosporine era - an analysis of risk factors. Transplantation 1991: 51: 343.
3. Weir MR, Fink JC. Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999: 34: 1.
4. Cosio FG, Pesavento TE, Kim S et al. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002: 62: 1440.
5. Montori VM, Basu A, Erwin PJ et al. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002: 25: 583.
6. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003: 3: 178.
7. Woodward RS, Schnitzler MA, Baty J et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003: 3: 590.
8. Gonzalez-Posada JM, Hernandez D, Genis BB, Perez JG, Sanchez MR. Impact of diabetes mellitus on kidney transplant recipients in Spain. Nephrol Dial Transplant 2004: 19(Suppl 3): iii57.
9. Cosio FG, Kudva Y, Van Der Velde M et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005: 67: 2415.
10. Araki M, Flechner SM, Ismail HR et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation 2006: 81: 335.
11. Shah T, Kasravi A, Huang E et al. Risk factors for development of new-onset diabetes mellitus after renal transplantation. Transplantation 2006: 82: 1673.
12. Valderhaug TG, Hjelmesaeth J, Rollag H et al. Reduced incidence of new-onset posttransplantation diabetes mellitus during the last decade. Transplantation 2007: 84: 1125.
13. Burroughs TE, Swindle J, Takemoto S et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation 2007: 83: 1027.
14. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008: 19: 1411.
15. Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008: 3: 814.
16. Bayer ND, Cochetti PT, Kumar MSA et al. Association of metabolic syndrome with development of new-onset diabetes after transplantation. Transplantation 2010: 90: 861.
17. Luan FL, Steffick DE, Ojo AO. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. Transplantation 2011: 91: 334.
18. Valderhaug TG, Hjelmesaeth J, Hartmann A et al. The association of early post-transplant glucose levels with long-term mortality. Diabetologia 2011: 54: 1341.
19. Guerra G, Ilahe A, Ciancio G. Diabetes and kidney transplantation: past, present, and future. Curr Diab Rep 2012: 12: 597.
20. Schweer T, Gwinner W, Scheffner I et al. High impact of rejection therapy on the incidence of post-transplant diabetes mellitus after kidney transplantation. Clin Transplant 2014: 28: 512.
21. Roth D, Milgrom M, Esquenazi V, Fuller L, Burke G, Miller G. Posttransplant hyperglycemia. Transplantation 1989: 47: 278.
22. Vesco L, Busson M, Bedrossian J et al. Diabetes mellitus after renal transplantation: characteristics, outcome, and risk factors. Transplantation 1996: 61: 1475.
23. Maes BD, Kuypers D, Messiaen T et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation 2001: 72: 1655.
24. Boots JMM, Van Duijnhoven EM, Christiaans MHL, Wolffenbuttel BHR, Van Hooff JP. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002: 13: 221.
25. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004: 4: 583.
26. Markell M. New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management. Am J Kidney Dis 2004: 43: 953.
27. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005: 16: 3128.
28. Yates CJ, Fourlanos S, Hjelmesaeth J, Colman PG, Cohney SJ. New-onset diabetes after kidney transplantation - changes and challenges. Am J Transplant 2012: 12: 820.
29. Rostaing L, Cantarovich D, Mourad G et al., the CARMEN Study Group. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005: 79: 807.
30. Nematalla AH, Bakr MA, Gheith OA et al. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study. Exp Clin Transplant 2007: 2: 673.
31. Vincenti F, Schena FP, Paraskevas S et al., on behalf of the FREEDOM Study Group. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008: 8: 307.
32. Woodle ES, First MR, Pirsch J et al., for the Astellas Corticosteroid Withdrawal Study Group. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (day 7) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008: 248: 564.
33. Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010: 89: 1.
34. Mayer AD, Dmitrewski J, Squifflet JP et al., for the European Tacrolimus Multicenter Renal Study Group. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 1997: 359: 741.
35. Ekberg H, Tedesco-Silva H, Demirbas A et al., for the ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007: 357: 2562.
36. Vincenti F, Friman S, Scheuermann E et al., on behalf of the DIRECT (Diabetes Incidence after Renal Transplantation): Neoral C2 Monitoring versus Tacrolimus Investigators. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007: 7: 1506.
37. Ciancio G, Burke GW, Gaynor JJ et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004: 77: 244.
38. Ciancio G, Burke GW, Gaynor JJ et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 yr. Transplantation 2004: 77: 252.
39. Ciancio G, Burke GW, Gaynor JJ et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. Transplantation 2006: 81: 845.
40. Guerra G, Ciancio G, Gaynor JJ et al. Randomized trial of immunosuppressive regimens in renal transplantation. J Am Soc Nephrol 2011: 22: 1758.
41. Ciancio G, Burke GW, Gaynor JJ et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005: 80: 457.
42. Ciancio G, Burke GW, Gaynor JJ et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow up. Clin Transplant 2008: 22: 200.
43. Ciancio G, Gaynor JJ, Roth D et al. Randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in living donor renal transplantation. Transplant Proc 2010: 42: 3503.
44. Ciancio G, Gaynor JJ, Guerra G et al. Randomized trial of three induction antibodies in kidney transplantation: long-term results. Transplantation 2014: 97: 1128.
45. Ciancio G, Burke GW, Gaynor JJ et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. Transplantation 2008: 86: 67.
46. Ciancio G, Gaynor JJ, Zarak A et al. Randomized trial of mycophenolate mofetil vs. enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis. Transplantation 2011: 91: 1198.
47. Ciancio G, Gaynor JJ, Sageshima J et al. Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation. Transplantation 2011: 92: 1348.
48. Ciancio G, Gaynor JJ, Sageshima J et al. Favorable outcomes with machine perfusion and longer pump times in kidney transplantation: a single-center, observational study. Transplantation 2010: 90: 882.
49. Solez K, Axelsen RA, Benediktsson H et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993: 44: 411.
50. Solez K, Colvin RB, Racusen LC et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN). Am J Transplant 2007: 7: 518.
51. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011: 34(Suppl 1): S62.
52. The International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009: 32: 1327.
53. Kaplan B, Meier-Kriesche HU, Napoli KL, Kahan BD. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 1998: 63: 48.
54. Felipe CR, Park SI, Pinheiro-Machado PG et al. Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. Fund Clin Pharmacol 2009: 23: 625.
55. Chakkera HA, Weil EJ, Swanson CM et al. Pretransplant risk score for new-onset diabetes after kidney transplantation. Diabetes Care 2011: 34: 2141.